Kbi-098

: A prominent small molecule being developed by BioVersys in collaboration with GSK to treat tuberculosis. It is designed to overcome antibiotic resistance and is currently in Phase 2 clinical trials.

: The Bureau often publishes annual reports or specific legislative documents that may use numbered designations (e.g., "98" referring to the year 1998 or a specific case file). KBI-098

The identifier appears to be a combination of terms that relate to several distinct professional and scientific fields. To help clarify which "KBI-098" you are referring to, below is an analysis of how these components are typically used in specialized sectors: 1. Pharmacology and Drug Development : A prominent small molecule being developed by

"KBI" is the standard abbreviation for the . The identifier appears to be a combination of

There is no definitive widely recognized entity, chemical compound, or project known as .